These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 23840792)
1. Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. Fozzatti L; Park JW; Zhao L; Willingham MC; Cheng SY PLoS One; 2013; 8(6):e67954. PubMed ID: 23840792 [TBL] [Abstract][Full Text] [Related]
2. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Fozzatti L; Lu C; Kim DW; Park JW; Astapova I; Gavrilova O; Willingham MC; Hollenberg AN; Cheng SY Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17462-7. PubMed ID: 21987803 [TBL] [Abstract][Full Text] [Related]
3. Genetic and Pharmacological Targeting of Transcriptional Repression in Resistance to Thyroid Hormone Alpha. Freudenthal B; Shetty S; Butterfield NC; Logan JG; Han CR; Zhu X; Astapova I; Hollenberg AN; Cheng SY; Bassett JHD; Williams GR Thyroid; 2019 May; 29(5):726-734. PubMed ID: 30760120 [No Abstract] [Full Text] [Related]
4. Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α. Fozzatti L; Kim DW; Park JW; Willingham MC; Hollenberg AN; Cheng SY Proc Natl Acad Sci U S A; 2013 May; 110(19):7850-5. PubMed ID: 23610395 [TBL] [Abstract][Full Text] [Related]
5. NCOR1 modulates erythroid disorders caused by mutations of thyroid hormone receptor α1. Han CR; Park S; Cheng SY Sci Rep; 2017 Dec; 7(1):18080. PubMed ID: 29273766 [TBL] [Abstract][Full Text] [Related]
6. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Lu C; Zhu X; Willingham MC; Cheng SY Oncogene; 2012 Apr; 31(16):2007-16. PubMed ID: 21909131 [TBL] [Abstract][Full Text] [Related]
7. NCoR1-independent mechanism plays a role in the action of the unliganded thyroid hormone receptor. Mendoza A; Astapova I; Shimizu H; Gallop MR; Al-Sowaimel L; MacGowan SMD; Bergmann T; Berg AH; Tenen DE; Jacobs C; Lyubetskaya A; Tsai L; Hollenberg AN Proc Natl Acad Sci U S A; 2017 Oct; 114(40):E8458-E8467. PubMed ID: 28923959 [TBL] [Abstract][Full Text] [Related]
8. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276 [TBL] [Abstract][Full Text] [Related]
9. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Kim WG; Park JW; Willingham MC; Cheng SY Endocrinology; 2013 Aug; 154(8):2936-47. PubMed ID: 23748362 [TBL] [Abstract][Full Text] [Related]
10. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Guigon CJ; Zhao L; Willingham MC; Cheng SY Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818 [TBL] [Abstract][Full Text] [Related]
11. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor. Zhao L; Zhu X; Won Park J; Fozzatti L; Willingham M; Cheng SY Endocrinology; 2012 Oct; 153(10):5090-100. PubMed ID: 22919057 [TBL] [Abstract][Full Text] [Related]
12. A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant. Kim DW; Park JW; Willingham MC; Cheng SY Hum Mol Genet; 2014 May; 23(10):2651-64. PubMed ID: 24381310 [TBL] [Abstract][Full Text] [Related]
13. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer. Park S; Willingham MC; Qi J; Cheng SY Endocr Relat Cancer; 2018 Oct; 25(10):865-877. PubMed ID: 29914872 [TBL] [Abstract][Full Text] [Related]
14. Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors. Fozzatti L; Lu C; Kim DW; Cheng SY Mol Endocrinol; 2011 Jun; 25(6):908-21. PubMed ID: 21474540 [TBL] [Abstract][Full Text] [Related]
15. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Battaglia S; Maguire O; Thorne JL; Hornung LB; Doig CL; Liu S; Sucheston LE; Bianchi A; Khanim FL; Gommersall LM; Coulter HS; Rakha S; Giddings I; O'Neill LP; Cooper CS; McCabe CJ; Bunce CM; Campbell MJ Carcinogenesis; 2010 Sep; 31(9):1650-60. PubMed ID: 20466759 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model. Park JW; Han CR; Zhao L; Willingham MC; Cheng SY Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408 [TBL] [Abstract][Full Text] [Related]
17. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. Ying H; Willingham MC; Cheng SY Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082 [TBL] [Abstract][Full Text] [Related]
18. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Lu C; Zhao L; Ying H; Willingham MC; Cheng SY Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Furuya F; Lu C; Willingham MC; Cheng SY Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507 [TBL] [Abstract][Full Text] [Related]
20. Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors. Vella KR; Ramadoss P; Costa-E-Sousa RH; Astapova I; Ye FD; Holtz KA; Harris JC; Hollenberg AN Mol Cell Biol; 2014 May; 34(9):1564-75. PubMed ID: 24550004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]